GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(-16.67%)
USD 0.0
(-16.67%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 77.00 | 425.00 | 890.00 |
| Cost of Revenue | - | - | 2412.00 | 37.68 Thousand | 154.00 | 207.00 |
| Gross Profit | - | - | -2412.00 | -37.6 Thousand | 271.00 | 683.00 |
| Operating Expenses | 1.86 Million | 1.26 Million | 9.09 Million | 266.06 Thousand | 316.14 Thousand | 351.73 Thousand |
| Selling, General and Administrative Expenses | 1.86 Million | 1.26 Million | 9.09 Million | 266.06 Thousand | 316.14 Thousand | 351.73 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | -152.39 Thousand | -419.9 Thousand | - | - | -1719.00 |
| Cost and Expenses | 1.86 Million | 1.26 Million | 9.09 Million | 303.74 Thousand | 316.29 Thousand | 351.94 Thousand |
| Operating Income | -1.86 Million | -1.26 Million | -9.09 Million | -303.67 Thousand | -315.87 Thousand | -351.05 Thousand |
| Interest Expense | 91.6 Thousand | 70.34 Thousand | 287.49 Thousand | 238.06 Thousand | 360.36 Thousand | 103.49 Thousand |
| Income Tax Expense | - | 152.39 Thousand | -132.4 Thousand | 238.06 Thousand | 360.36 Thousand | -258.7 Thousand |
| Earnings before Tax | -1.94 Million | -1.48 Million | -9.8 Million | -541.73 Thousand | -675.07 Thousand | -816.74 Thousand |
| Net Income | -1.94 Million | -1.64 Million | -9.66 Million | -779.79 Thousand | -1.03 Million | -816.74 Thousand |
| Earnings Per Share Basic | -0.00 | -0.00 | -0.02 | -0.00 | -0.01 | -0.01 |
| Earnings Per Share Diluted | -0.00 | -0.00 | -0.02 | -0.00 | -0.01 | -0.01 |
| Weighted Average Shares Outstanding | 827.32 Million | 628.53 Million | 482.09 Million | 298.09 Million | 104.77 Million | 56.51 Million |
| Weighted Average Shares Outstanding (Diluted) | 827.32 Million | 628.53 Million | 482.09 Million | 298.09 Million | 104.77 Million | 56.51 Million |
| Gross Margin | - | - | - | -488.38 | 0.64 | 0.77 |
| EBIT Margin | - | - | - | -3926.52 | -742.11 | -396.24 |
| Profit Margin | - | - | - | -10.12 Thousand | -2436.32 | -917.69 |
| EBITDA | 6724.00 | -1.26 Million | -9.09 Million | -302.34 Thousand | -314.23 Thousand | -713.13 Thousand |
| Earnings Before Tax Margin | - | - | - | -3943.78 | -743.22 | -394.44 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 193.35 Thousand | 167.58 Thousand | 155.87 Thousand | 1.26 Million | 287.78 Thousand | 1.27 Million |
| Selling, General and Administrative Expenses | 193.35 Thousand | 167.58 Thousand | 155.87 Thousand | - | 287.78 Thousand | 1.27 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | -6724.00 | 6724.00 |
| Cost and Expenses | 193.35 Thousand | 167.58 Thousand | 155.87 Thousand | 1.26 Million | 287.78 Thousand | 1.27 Million |
| Operating Income | -193.35 Thousand | -167.58 Thousand | -155.87 Thousand | -1.26 Million | -287.78 Thousand | -1.27 Million |
| Interest Expense | 4304.00 | 7379.00 | 7888.00 | -70.34 Thousand | 62.78 Thousand | 9970.00 |
| Income Tax Expense | -193.35 Thousand | -167.58 Thousand | -155.87 | -1864.37 | -36.99 Thousand | 9970.00 |
| Earnings before Tax | -197.66 Thousand | -174.96 Thousand | -163.75 Thousand | -1.48 Million | -350.57 Thousand | -1.28 Million |
| Net Income | -197.66 Thousand | -174.96 Thousand | -163.75 Thousand | -1.48 Million | -350.57 Thousand | -1.28 Million |
| Earnings Per Share Basic | -0.00 | -0.00 | -0.00 | - | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | -0.00 | -0.00 | - | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 1.2 Billion | 1.12 Billion | 1 Billion | 827.32 Million | 996.11 Million | 843.52 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.2 Billion | 1.12 Billion | 1 Billion | 827.32 Million | 996.11 Million | 843.52 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -193.35 Thousand | -167.58 Thousand | -155.87 Thousand | - | -287.78 Thousand | -1.27 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
NCL
PCAR
300380
3648
BETRF
AUROPHARMA